What's the "Interest" in FDA Drug Advisory Committee Conflicts of Interest? / Joseph Golec, John Vernon.

Format:

Book

Author/Creator:

Golec, Joseph.

Contributor:

National Bureau of Economic Research.

Vernon, John.

Series:

Working Paper Series (National Bureau of Economic Research) no. w14932.

NBER working paper series no. w14932

Language:

English

Physical Description:

1 online resource: illustrations (black and white);

Place of Publication:

Cambridge, Mass. National Bureau of Economic Research 2009.

Summary:

Food and Drug Administration (FDA) drug advisory committee members sometimes have financial interests tied to drug companies. Congress and the public have become concerned that these financial interests lead to conflicts of interest. They conclude that the conflicts bias committee recommendations, and lead to unsafe or ineffective drugs being approved for public consumption, or, conversely, delays in approval of safe and effective drugs. Our paper provides empirical evidence, based on an event study methodology, that advisory committee meetings lead to weak or statistically insignificant effects on stock prices and hence equity values of regulated companies assumed to be affected by the particular matters coming before committee meetings.

Notes:

Print version record

April 2009.